| HOME >> BIOLOGY >> TECHNOLOGY |
Total costs and
expenses 69,847 76,490 240,199 194,509
Income (loss) from
operations (58,173) (65,434) (204,683) (165,183)
Net investment income
(expense) (3,891) (1,823) (11,005) (4,372)
Charge for impaired
investments (6,049) - (6,049) -
Gain on sale of long-term
equity investment - - 32,518 -
Income (loss) before taxes (68,113) (67,257) (189,219) (169,555)
Provision for income taxes - - - -
Net income (loss) $(68,113) $(67,257) $(189,219) $(169,555)
Net income (loss) per share,
basic and diluted $(0.50) $(0.50) $(1.40) $(1.26)
Weighted average shares
outstanding, basic &
diluted 135,486,677 134,394,174 135,371,579 134,220,053
(a) Includes stock-based compensation expense of $2,603 ($0.02 per share) and $3,474 ($0.03 per share) for the three months ended September 30, 2008 and 2007, respectively. Includes stock-based compensation expense of $7,837 ($0.06 per share) and $9,824 ($0.07 per share) for the nine months ended September 30, 2008 and 2007, respectively.
(b) Includes stock-based compensation expense of $2,041 ($0.02 per
share) and $2,261 ($0.02 per share) for the three months ended September
30, 2008 and 2007, respectively. Includes stock-based compensation expense
of $6,111 ($0.05 per share) and $6,606 ($0.05 per share) for the nine
months ended September 30, 2008 and 2007, respectively.
CONSOLIDATED BALANCE SHEET DATA:
As of As of
September 30, 2008 Dec
'/>"/>
| SOURCE Human Genome Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved |